Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Gto Pharma LLC has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The portfolio's current activity is handled by 1 distinct examiner and 1 distinct art unit. KWON, YONG SOK is the busiest examiner, with 1 pending action currently under review.
This distribution indicates a highly focused prosecution effort within a specific niche of Biotechnology & Pharmaceuticals. Since only 1 distinct examiner is involved, the company's immediate patent prospects depend on the feedback from KWON, YONG SOK. Practitioners should analyze the examiner's past decisions to better understand the potential challenges for the 1 pending office action.
The singular focus on 1 distinct art unit and one examiner provides a clear but narrow path for the company's current intellectual property strategy. Success in this 1 action will be a critical step for the company's overall patent goals. Practitioners should monitor the specific procedural history of this matter to ensure all examiner requirements are met efficiently and to predict the future trajectory of the portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KWON, YONG SOK | 1 | 23.8% | +42.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18668135 | COMPOUNDS AND FORMS OF TREATMENT FOR FEMALE SEXUAL DISORDERS | KWON, YONG SOK | 50d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18668135 | COMPOUNDS AND FORMS OF TREATMENT FOR FEMALE SEXUAL DISORDERS | KWON, YONG SOK | 50d |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18668135 | COMPOUNDS AND FORMS OF TREATMENT FOR FEMALE SEXUAL DISORDERS | KWON, YONG SOK | 1613 | §101§102§103§112Other | Non-Final OA | 50d | Pending | May 18, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGto Pharma LLC has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Yong Sok Kwon has the most, with 1 of Gto Pharma LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.